A Systematic Review Of Brevsicapus Agents For Cerbral Infarction

Objective: Systematic review of clinical treatment of cerebral infarction Erigeron preparation efficacy, safety and pharmacoeconomics.Methods: Randomized controlled trials of treatment of cerebral infarction Breviscapine literature for systematic reviews. Electronic retrieval Chinese Bionmedical Literature Database, Chinese Academic Journal Full-test Database, Chinese Academic Journal, Chinese Medical Science and Technology Literature Database,Evidence-Based Chinese Medicine Database,Chinese Excellent Dissertations Full-text database ,Medline,Cochrane Library,etc;hand search"Journal of Traditional Chinese Medicine""Traditional and Western Medicine""Shandong Traditional Chinese Medicine; supplementary appendix to retrieve relevant articles identified references.Screening eligible studies, two reviewers independently extracted data, according to study quality score evaluation of the quality, the use of Cochrane Collaboration software provided RevMan4.2 heterogeneity test, Meta-analysis, funnel plot analysis and sensitivity analysis menthod of statistical data.Results:Totally out of 173 literature may be related,by reading the summary and the full-text documents were collected from 96 randomized controlled trials, of which 76 met the inclusion criteria because they do not rule out,a total of 20 articles were included in this study, including 3071 cases patients. All are published in Chinese literature research,study sites are in china. The results showed that: Deng Hua clinical efficacy than the control group preparations (90.54% VS 73.69%; OR 3.61; 95% CI 2.93 ~ 4.44; P <0.01); whole blood viscosity (WMD =- 0.86; 95% CI-0.92 ~ - 0.81; P <0.001); plasma viscosity (WMD =- 0.21 95% CI-0.22 ~ -0.20; P <0.001); fibrinogen (WMD =- 1.13; 95% CI-1.14 ~ -1.12; P <0.001 ; hematocrit (WMD =- 2.58; 95% CI-2.70 ~ -2.47; P <0.001). Funnel plot shows asymmetry and publication bias may be related to clinical trial design. No serious adverse reactions. Lack of Pharmacoeconomic evaluation of Erigeron.Conclusion: Meta-analysis showed an improvement in cerebral infarction patients Erigeron agents become targets and whole blood micro-circulation, increase cerebral blood flow, and the safety range, clinical side effects. Treatment of cerebral infarction due Dengzhanhua methodology of randomized controlled trials of low quality, there is the potential clinical heterogeneity and publication bias, and the index of other factors, reducing the reliability of the above conclusions, it is still evaluating the system Erigeron agents can not be sure proof of the efficacy and the safety of cerebral infarction.